Clinical outcomes of AML patients treated with Azacitidine in Portugal: a retrospective multicenter study

António Almeida; Ana Rita Ferreira; Maria João Costa; Sofia Silva; Khalil Alnajjar; Isabel Bogalho; Francesca Pierdomenico; Susana Esteves; Mafalda Alpoim; Gil Braz; Emilia Cortesão; Ricardo Pinto

doi:10.1016/j.lrr.2016.12.002

Clinical outcomes of AML patients treated with Azacitidine in Portugal: a retrospective multicenter study

António Almeida^*, Ana Rita Ferreira, Maria João Costa, Sofia Silva, Khalil Alnajjar, Isabel Bogalho, Francesca Pierdomenico, Susana Esteves, Mafalda Alpoim, Gil Braz, Emilia Cortesão, Ricardo Pinto

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Retrospective data was collected from 77 elderly acute myeloid leukemia (AML) patients treated with Azacitidine (AZA) and 50 elderly AML patients treated with intensive chemotherapy (IC) from 4 Portuguese Hospitals. Median OS was 10.6 months in those receiving AZA as 1st line. Response (overall response rate 44%) had a significant impact on overall survival (p=<0.0001). Median OS of the comparator IC cohort was significantly inferior to that observed in the cohort treated with AZA in first line (p=0.0104). These results support the efficacy of AZA in AML in the elderly in any line of treatment.

Original language	English
Pages (from-to)	6-10
Number of pages	5
Journal	Leukemia Research Reports
Volume	7
DOIs	https://doi.org/10.1016/j.lrr.2016.12.002
Publication status	Published - 2017
Externally published	Yes

Keywords

Acute myeloid leukemia
Azacitidine
Elderly
Hypomethylating agents

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.lrr.2016.12.002Licence: CC BY-NC-ND

Cite this

@article{91f3510428cf41b0b7817fc32255bae1,

title = "Clinical outcomes of AML patients treated with Azacitidine in Portugal: a retrospective multicenter study",

abstract = "Retrospective data was collected from 77 elderly acute myeloid leukemia (AML) patients treated with Azacitidine (AZA) and 50 elderly AML patients treated with intensive chemotherapy (IC) from 4 Portuguese Hospitals. Median OS was 10.6 months in those receiving AZA as 1st line. Response (overall response rate 44%) had a significant impact on overall survival (p=<0.0001). Median OS of the comparator IC cohort was significantly inferior to that observed in the cohort treated with AZA in first line (p=0.0104). These results support the efficacy of AZA in AML in the elderly in any line of treatment.",

keywords = "Acute myeloid leukemia, Azacitidine, Elderly, Hypomethylating agents",

author = "Ant{\'o}nio Almeida and Ferreira, {Ana Rita} and Costa, {Maria Jo{\~a}o} and Sofia Silva and Khalil Alnajjar and Isabel Bogalho and Francesca Pierdomenico and Susana Esteves and Mafalda Alpoim and Gil Braz and Emilia Cortes{\~a}o and Ricardo Pinto",

year = "2017",

doi = "10.1016/j.lrr.2016.12.002",

language = "English",

volume = "7",

pages = "6--10",

journal = "Leukemia Research Reports",

issn = "2213-0489",

publisher = "Elsevier Ltd.",

}

TY - JOUR

T1 - Clinical outcomes of AML patients treated with Azacitidine in Portugal

T2 - a retrospective multicenter study

AU - Almeida, António

AU - Ferreira, Ana Rita

AU - Costa, Maria João

AU - Silva, Sofia

AU - Alnajjar, Khalil

AU - Bogalho, Isabel

AU - Pierdomenico, Francesca

AU - Esteves, Susana

AU - Alpoim, Mafalda

AU - Braz, Gil

AU - Cortesão, Emilia

AU - Pinto, Ricardo

PY - 2017

Y1 - 2017

N2 - Retrospective data was collected from 77 elderly acute myeloid leukemia (AML) patients treated with Azacitidine (AZA) and 50 elderly AML patients treated with intensive chemotherapy (IC) from 4 Portuguese Hospitals. Median OS was 10.6 months in those receiving AZA as 1st line. Response (overall response rate 44%) had a significant impact on overall survival (p=<0.0001). Median OS of the comparator IC cohort was significantly inferior to that observed in the cohort treated with AZA in first line (p=0.0104). These results support the efficacy of AZA in AML in the elderly in any line of treatment.

AB - Retrospective data was collected from 77 elderly acute myeloid leukemia (AML) patients treated with Azacitidine (AZA) and 50 elderly AML patients treated with intensive chemotherapy (IC) from 4 Portuguese Hospitals. Median OS was 10.6 months in those receiving AZA as 1st line. Response (overall response rate 44%) had a significant impact on overall survival (p=<0.0001). Median OS of the comparator IC cohort was significantly inferior to that observed in the cohort treated with AZA in first line (p=0.0104). These results support the efficacy of AZA in AML in the elderly in any line of treatment.

KW - Acute myeloid leukemia

KW - Azacitidine

KW - Elderly

KW - Hypomethylating agents

UR - http://www.scopus.com/inward/record.url?scp=85008625228&partnerID=8YFLogxK

U2 - 10.1016/j.lrr.2016.12.002

DO - 10.1016/j.lrr.2016.12.002

M3 - Article

C2 - 28066705

AN - SCOPUS:85008625228

SN - 2213-0489

VL - 7

SP - 6

EP - 10

JO - Leukemia Research Reports

JF - Leukemia Research Reports

ER -

Clinical outcomes of AML patients treated with Azacitidine in Portugal: a retrospective multicenter study

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this